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Abstract  
 
Objective:  Monogenic diabetes, a young-onset form of diabetes, is often misdiagnosed as 
Type 1 diabetes, resulting in unnecessary treatment with insulin.  A screening approach for 
monogenic diabetes is needed to accurately select suitable patients for expensive diagnostic 
genetic testing.  We used C-peptide and islet autoantibodies, highly sensitive and specific 
biomarkers for discriminating Type 1 from non-Type 1 diabetes, in a biomarker screening 
pathway for monogenic diabetes.   
 
Research Design and Methods: We studied patients diagnosed ≤30y, currently <50y, in two 
UK regions with existing high detection of monogenic diabetes. The biomarker screening 
pathway comprised 3 stages: 1) Assessment of endogenous insulin secretion using urinary C-
peptide/creatinine ratio (UCPCR); 2) If UCPCR≥0.2nmol/mmol, measurement of GAD and 
IA2 islet autoantibodies; 3) If negative for both autoantibodies, molecular genetic diagnostic 
testing for 35 monogenic diabetes subtypes. 
 
Results: 1407 patients participated (1365 no known genetic cause, 34 monogenic diabetes, 
8 cystic-fibrosis-related diabetes).  386/1365(28%) had UCPCR≥0.2nmol/mmol. 
216/386(56%) of these patients were negative for GAD and IA2 and underwent molecular 
genetic testing.  17 new cases of monogenic diabetes were diagnosed (8 common MODY 
(Sanger sequencing), 9 rarer causes (next generation sequencing)) in addition to the 34 
known cases (estimated prevalence of 3.6% (51/1407) (95%CI: 2.7-4.7%)).  The positive 
predictive value was 20%, suggesting a 1-in-5 detection rate for the pathway.  The negative 
predictive value was 99.9%. 
 
Conclusions: The biomarker screening pathway for monogenic diabetes is an effective, 
cheap, and easily implemented approach to systematically screening all young-onset 
patients. The minimum prevalence of monogenic diabetes is 3.6% of patients diagnosed 
≤30y. 
 
 
Registered on Clinicaltrials.gov ref NCT01238380 
 
 
 
 
 
  
 3 
 
Introduction 
 
Correct classification of a patient’s diabetes is important to ensure they receive the most 
appropriate treatment and ongoing management.  The most common form of diabetes in 
children and young adults is Type 1 diabetes, accounting for over 90% of cases(1; 2).  Other 
forms of diabetes in this age group, such as monogenic diabetes (including Maturity Onset 
Diabetes of the Young (MODY)), or young-onset Type 2, are not often considered.  It is 
estimated that at least 80% of patients with MODY are misdiagnosed(3), and other rarer 
forms of monogenic diabetes often go unrecognized due to lack of awareness(4).  Patients 
with MODY or Type 2 diabetes misclassified as Type 1 diabetes will be treated with insulin, 
whereas non-insulin therapy would be more appropriate.  Diet and metformin are the 
treatment of choice in young Type 2 diabetes(5).  Patients with MODY due to mutations in 
the HNF1A or HNF4A  genes respond well to low dose sulphonylureas(6; 7) and those with 
MODY due to mutations in the GCK gene require no pharmacological treatment(8).  Getting 
a correct diagnosis for all forms of monogenic diabetes has important implications for 
management of an individual’s diabetes, their prognosis, and recognition of associated 
clinical features; it also allows appropriate counselling of  other family members regarding 
likely inheritance (4). 
 
Identifying patients with monogenic diabetes, particularly MODY, can be challenging.  
Monogenic diabetes is confirmed by molecular genetic testing, but this is expensive so 
testing all patients is not feasible.  An approach that could be used to enrich for monogenic 
diabetes, increasing the proportion identified in those who undergo genetic testing, would 
be helpful.  Clinical features can aid identification of those who may have an alternative 
diagnosis, and a probability calculator has been developed to help determine which patients 
are likely to have the most common forms of MODY(9).  However, this will not pick up other 
forms of monogenic diabetes and its performance is weaker for detecting MODY in insulin 
treated patients compared to non-insulin treated patients. 
 
An alternative approach to enrich for monogenic diabetes is to use biomarkers which have 
been shown to discriminate well between Type 1 and other forms of young onset diabetes. 
Type 1 diabetes is characterized by autoimmune destruction of the beta-cells in the 
pancreas leading to absolute insulin deficiency so two tests that could be used to diagnose 
Type 1 diabetes are islet autoantibodies (markers of the autoimmune process) and C-
peptide (a marker of insulin deficiency).  C-peptide has been shown to be a highly sensitive 
and specific biomarker for discriminating between Type 1 and Type 2 diabetes and MODY 3-
5 years after diagnosis(10; 11).  Urine C-peptide-Creatinine ratio (UCPCR) can be used to 
remove the need for blood samples, which may be of particular concern in the pediatric 
population, and means that the sample can easily be taken at home and posted to the 
laboratory(12).  GAD and IA2 islet autoantibodies also discriminate well between Type 1 and 
MODY, with cross sectional studies showing they are present in 80% of patients with Type 1 
diabetes and in less than 1% of patients with MODY(13).  These biomarkers have been used 
to screen for MODY in other studies(14; 15), but have been limited to pediatric cases only.  
Given the median age at diagnosis for MODY is 20 years (from UK referrals data(3)), and 
there is on average a delay of 13 years from diabetes diagnosis to a confirmed genetic 
diagnosis(16), it is crucial to study adults as well.  Furthermore the combined diagnostic 
performance of the two biomarkers as a screening pathway has not been formally assessed. 
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By excluding those with Type 1 diabetes using these two biomarkers we can obtain a smaller 
percentage of patients in whom diagnostic molecular testing for monogenic diabetes could 
be performed. We tested a screening pathway using both C-peptide and islet autoantibodies 
to exclude Type 1 diabetes in two populations with previously high pick-up rates of 
MODY(3), and performed genetic testing on all patients with significant endogenous insulin 
and absence of islet autoantibodies.  This allowed us to determine the prevalence of all 
monogenic diabetes subtypes in those diagnosed <30 years, and to calculate the positive 
and negative predictive values for the pathway. 
 
Research Design and Methods: 
Subjects 
Patients diagnosed aged 30 years or under, and currently aged under 50, in the catchment 
areas of the Royal Devon and Exeter NHS Foundation Trust (Exeter, UK) and Ninewells 
Hospital (Dundee, UK) were invited to take part in the study via the doctors looking after 
their medical care.  All patients with diabetes in this age group were eligible regardless of 
cause.  Both regions had existing high pick-up rates for MODY prior to the study due to 
research interests(3). Patients that consented provided samples as part of the biomarkers 
screening pathway (the UNITED study (Using pharmacogeNetics to Improve Treatment in 
Early-onset Diabetes (UNITED)), clinicaltrials.gov ref NCT01238380). 
 
Biomarker Screening Pathway 
All recruited patients followed the biomarker screening pathway (Figure 1): 
 
1. Assessment of endogenous insulin, in insulin treated patients, using urinary C-peptide 
creatinine ratio (UCPCR) 
A key determinant of requirement for insulin treatment is lack of endogenous insulin 
secretion, and UCPCR is an easy screening test that can be done at home. UCPCR was 
used to rule out the majority of Type 1 patients in the first stage of screening, with 
minimal patient burden.   
 
Insulin treated patients were asked to collect a urine sample two hours after the largest, 
carbohydrate containing meal of the day and to post this direct to the laboratory in a 
pack provided to allow analysis within 72 hours of sample collection, in line with assay 
stability(12). 
  
Urinary C-peptide was measured by an electrochemiluminescence immunoassay (intra-
assay coefficient of variation, 3.3%; interassay coefficient of variation, 4.5%) on a Roche 
Diagnostics E170 analyzer (Mannheim, Germany)(12). The lower limit of the C-peptide 
assay was 0.03nmol/l. Urinary creatinine was analyzed on the Roche P800 platform 
using creatinine Jaffé reagent (standardized against isotope dilution mass spectrometry) 
and used to calculate UCPCR (nmol/mmol).  Patients with UCPCR>0.2nmol/mmol were 
considered to have significant endogenous insulin secretion(10). 
 
2. Islet autoantibody measurement in patients with significant endogenous insulin 
Islet autoantibodies (GAD and IA2) were measured in patients who tested positive for 
UCPCR (UCPCR>0.2nmol/mmol) or who were non-insulin treated.  In order to minimize 
taking blood samples, particularly in children, the local pathology databases were 
checked for previous GAD and IA2 results and these were used if available.  Patients with 
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no previous islet autoantibody results  were invited to attend an appointment with the 
study’s research nurse to provide blood samples for islet autoantibody testing and DNA.   
 
GAD and IA2 antibody analysis was performed using commercial ELISA assays (RSR Ltd., 
Cardiff, UK) and a Dynex DSX automated ELISA system (Launch Diagnostics, Longfield, 
UK)(13). Both methods are highly specific and sensitive, (GAD antibodies 98% and 84% 
and IA-2 antibodies 99% and 74%, respectively). The laboratory participates in the 
Diabetes Autoantibody Standardization Programme.  Patients were considered positive 
for antibodies if their results were >99th centile (64 WHOunits/ml for GAD and 15 
WHOunits/ml for IA2)(13). 
 
3. Diagnostic molecular genetic testing for monogenic diabetes in patients with significant 
endogenous insulin and negative antibody results 
a) Sequencing of three MODY genes, the most common forms of monogenic diabetes.  
For all patients who were negative for both GAD and IA2 antibodies with significant 
endogenous insulin, DNA sequencing of HNF1A, HNF4A and GCK was performed by 
PCR amplification of purified genomic DNA, followed by Sanger DNA sequencing of 
each gene’s exons and flanking intronic regions.  Dosage analysis of HNF1A, HNF4A 
and GCK for partial and whole gene deletions was also performed by multiplex 
ligation-dependent probe amplification (MLPA) using the MRC-Holland MODY MLPA 
kit-P241-B1. 
b) Targeted next generation sequencing for 35 genes in which mutations are known to 
cause monogenic diabetes.  If no pathogenic mutation was identified in HNF1A, 
HNF4A or GCK, further targeted next generation sequencing was performed for 
mutations in 35 monogenic diabetes genes (all genes where mutations are known to 
cause MODY, neonatal diabetes, and other genetic diabetes syndromes), using a 
custom Agilent SureSelect exon-capture assay (Agilent Technologies, Santa Clara, CA, 
USA)(17) (see supplemental materials and Supplemental Table S1 for methodology, 
sensitivity and details of genes tested). 
 
Statistical analysis 
For comparing new cases diagnosed through the screening pathway to known cases of 
monogenic diabetes, and for comparing the biomarker screening pathway with an approach 
using clinical features (including the MODY probability calculator(9)) to detect monogenic 
diabetes, variables were categorical and so chi-squared and Fisher’s exact tests were used.   
 
Prevalence of MODY 
The prevalence of MODY in this population was determined as the proportion of positive 
cases, (including both known MODY that were recruited and those identified through the 
study), out of the total recruited.   
 
To determine whether there was any potential bias in recruitment of MODY patients that 
may affect our prevalence estimate, we also obtained summary data on the number of 
patients with previously confirmed monogenic diabetes in each study area who had not 
been recruited into this study. 
 
Positive and Negative Predictive Values of Pathway 
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Calculating the prevalence in this population allows us to determine the positive and 
negative predictive values for the pathway, the most important statistics for the clinician.  
Positive and negative predictive values were calculated as: 
post-test odds = pre-test odds x positive likelihood ratio  
where pre-test odds is prevalence/(1-prevalence) and positive likelihood ratio is 
sensitivity/(1-specificity). Positive predictive value (PPV; equivalent to post-test probability) 
is post-test odds/(1+post-test odds).  Negative predictive value (NPV) was calculated 
similarly, but using a negative likelihood ratio (1-sensitivity/specificity), with negative post-
test probability equal to 1 - NPV.  Number needed to test was calculated as 1/PPV. 
 
Performance of the pathway – sensitivity and specificity 
The key question is how well, if applied to a whole population, do the biomarkers perform in 
a pathway for identifying new cases.  Screening literature emphasises the difference 
between programme sensitivity/specificity and test sensitivity/specificity, where assessing 
the sensitivity/specificity of a screening programme such as this, necessarily requires 
approximation using multiple data sources(18).  As this was a population based study, rather 
than a case-control study, formal assessments of sensitivity and specificity (as normally 
conducted using a 2x2 table) of the pathway were limited due to the rarity of monogenic 
diabetes (meaning a small sample size of true positive cases of monogenic diabetes), and 
the expense of genetic testing (restricting confirmation of all the true negative non-
monogenic cases).   
 
Assessments of sensitivity of the components of the pathway for detecting monogenic 
diabetes have been carried out in larger case control cohorts (n=508 monogenic diabetes 
cases for islet autoantibodies (99% sensitivity)(13), n=160 for UCPCR (99% sensitivity, both 
studies combined(10; 11))), so it is more appropriate to use these estimates. We assumed a 
98% sensitivity for both combined, based on these larger studies (assuming 1% missed due 
to false negative UCPCR and 1% due to false positive islet autoantibodies).  However, the 
detection rate in all true monogenic cases in this pathway will be calculated for comparison. 
 
Calculation of the specificity is limited as we have not performed genetic testing on all C-
peptide negative patients.  Previous larger studies have shown <1% of patients are 
missed(10; 11; 13).  However, specificity of the biomarkers in these studies was assessed 
using gold standard Type 1 diabetes as the comparison group, rather than all non-MODY 
patients in this age range, and so likely overestimates the performance due to spectrum 
bias(19).  We therefore, calculated specificity based on one minus the false positive rate of 
the pathway (i.e. proportion UCPCR positive/antibody negative, but not having a confirmed 
diagnosis of monogenic diabetes on subsequent genetic testing).  This assumes all patients 
negative according to the pathway are true negatives.  As an additional test of this 
assumption, a subset of patients negative for islet autoantibodies received genetic testing 
for the 3 main MODY genes and the proportion of MODY was calculated. 
 
Health economic evaluation of the pathway is addressed in a separate paper (Peters et al. 
manuscript under review, protocol and conference abstract available(20; 21)). 
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Results: 
 
Subjects  
The flow of subjects through the study is shown in Figure 2.  2288 patients were eligible in 
area and 1418 subjects (62%) in total consented to the study and were recruited: 716 from 
the Exeter area, 702 from Dundee.  11 patients dropped out (9 did not provide blood 
samples for antibody testing, and 2 did not provide samples for DNA testing).  Of the 1407 
remaining patients, 1365 had no known genetic cause for their diabetes.  Characteristics of 
these patients are shown in Supplemental Table S2 and subsequent results on the screening 
pathway are based on these patients.  42 patients had a known genetic cause for their 
diabetes prior to participating in this pathway: 34 patients had confirmed monogenic 
diabetes (see Table 2 for details) and 8 patients had Cystic-fibrosis related diabetes.   
 
Biomarker screening pathway identifies 17 new cases of monogenic diabetes (Figure 2) 
Excluding drop-outs, 1281 (94%) of 1365 patients with no known genetic cause for their 
diabetes were insulin treated and provided a sample for UCPCR testing.  2 patients were 
anuric due to renal failure and so went straight on to antibody testing.  979 of these patients 
(76%) had minimal endogenous insulin secretion (UCPCR <0.2nmol/mmol) indicating a 
diagnosis of Type 1 diabetes, so received no further testing   
 
Islet autoantibodies were tested in the 84 non-insulin treated patients, 300 UCPCR positive 
patients, and the 2 anuric patients.  170/386 (44%) tested positive for GAD and/or IA2 
antibodies, confirming islet autoimmunity and hence a diagnosis of Type 1 diabetes.  So 
these patients received no further testing.  
 
Sanger sequencing for the 3 commonest MODY genes was undertaken in 216 patients (16% 
of the whole cohort).  8 patients tested positive confirming a diagnosis of MODY: 5 HNF1A, 2 
HNF4A, and 1 GCK (Table 1, Figure 2).   
 
Of the 208 who tested negative for the common MODY genes, additional testing by targeted 
next generation sequencing identified mutations in genes associated with monogenic 
diabetes in a further 8 patients and 1 patient had a mutation in POLD1 identified through 
exome sequencing (see Table 1, Figure 2).  
 
New cases of monogenic diabetes identified were more likely to be rarer causes and 
atypical (Supplemental Figure S1) 
More of the new cases of monogenic diabetes identified had mutations in genes other than 
the 3 most common forms of MODY. (25/34 (74%) of those diagnosed prior to the study had 
mutations in HNF1A, HNF4A, or GCK compared with 8/17 (47%) identified from Sanger 
sequencing as part of the biomarker screening pathway, p=0.06).  Those diagnosed with 
monogenic diabetes as part of the study were less likely to have a parent known to be 
affected than those with a previous known monogenic diagnosis (8/17 (47%) v 29/34 (85%), 
p=0.007). 
 
Minimum prevalence of monogenic diabetes of 3.6% in those diagnosed <30y, currently 
under 50y  
We found 51 cases of monogenic diabetes (which represents a further 50% (n=17) in 
addition to the 34 previously diagnosed) out of 1407 recruited patients providing a 
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prevalence of 3.6% (95% CI: 2.7 to 4.7%) in patients diagnosed under 30 and currently under 
50 years.   
 
From the database of UK referrals, we identified 26 patients with a diagnosis of monogenic 
diabetes in the Exeter and Tayside regions, who met study inclusion criteria, but were not 
recruited to the UNITED study.  Therefore, the proportion of known monogenic diabetes 
prior to the study in the recruited population (34/1407 (2.4%)) was similar to the proportion 
in the non-recruited population (26/870 (3.0%)) (p=0.4), suggesting no overall bias in 
recruitment.  More of the non-recruited cases had MODY caused by mutations in the GCK 
gene but this was not significant given the small numbers (46% v 26%, p=0.1). There was no 
difference in terms of age at diagnosis (mean 18 v 19y, p=0.5), age at time of recruitment 
(using 2011 for non-recruited patients) (32 v 32y, p=0.98) or gender (35% v 45% male, 
p=0.4).   
 
Performance of the pathway (Table 2): 
In line with what was expected given larger studies of the diagnostic accuracy of UCPCR and 
islet autoantibodies and the known pathophysiology of monogenic diabetes, all cases with 
previously diagnosed monogenic diabetes who provided all samples for the pathway (n=21) 
were UCPCR positive and antibody negative.  Similarly, all antibody positive patients with 
DNA available (n=47) tested negative for the three main MODY genes so no additional 
MODY cases were picked up in this group.   
 
199/1348 (15%) of patients were put forward for genetic testing who were not found to 
have monogenic diabetes (i.e. 15% false positive rate, so 85% specificity). Assuming a 98% 
sensitivity and 85% specificity, the positive predictive value for the pathway is 20%, 
suggesting a 1 in 5 pick-up rate for monogenic diabetes, a 5.6-fold increase in probability 
over the background prevalence alone.  The negative predictive value was 99.9%, indicating 
the probability of having monogenic diabetes if you are UCPCR negative or islet 
autoantibody positive is 0.1% (1 in 1000). 
 
Comparison of biomarker screening pathway with clinical features (Table 2) 
If genetic testing had been limited to the standard clinical criteria for MODY (age at 
diagnosis <25y, non insulin requiring and a parent known to be affected with diabetes), 
fewer patients would have required testing (n=33) leading to a higher pick-up rate and 
positive predictive value (PPV=57.6%) than the biomarker pathway, but the majority of 
monogenic cases would have been missed (63% compared with 0% for the biomarker 
pathway). The MODY probability calculator also had a higher positive predictive value 
(PPV=40.4%), but missed more cases (55%) compared with the biomarker pathway. 
 
 
Conclusions 
 
The biomarker screening pathway for monogenic diabetes is a systematic, cheap (UK UCPCR 
cost=£10.80, antibodies cost=£20), and easily implemented approach to screening all 
patients with young-onset diabetes in a clinic or population that helps identify suitable 
patients for molecular diagnostic genetic testing. The pathway picked up new cases of 
monogenic diabetes, even in areas of existing high detection due to research interests in the 
regions.  We found 3.6% of patients diagnosed less than 30 years of age have monogenic 
diabetes.  In areas where no cases have been identified, we estimate that 1 in 5 patients 
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referred for genetic testing as a result of the pathway will have monogenic diabetes which is 
a 5.6-fold higher detection rate than if all patients in this age range received genetic testing.  
The high negative predictive value of 99.9% indicates it is an extremely effective approach 
for ruling out monogenic diabetes. 
 
There have been relatively few studies that have systematically screened whole populations 
for monogenic diabetes.  The majority of studies have been in pediatric populations only(14; 
15; 22-26), with only two studies that have screened adults(27; 28).  No other study has 
systematically screened a whole population of both adults and children together. Only 8/51 
(16%) of patients with a genetic diagnosis of monogenic diabetes in our cohort were in the 
pediatric age range (<20y) at the time of recruitment, highlighting the importance of looking 
for monogenic diabetes in adult diabetes clinics. This may explain why the prevalence we 
find is higher than any of the previous pediatric studies. 
 
The strength of our pathway is the integration of two biomarkers (C-peptide and islet 
autoantibodies (both GAD and IA2)), rather than relying on clinical features.  This offers a 
simple approach that does not require specific clinician interpretation or complex 
algorithms of different combinations of features. We showed that by using clinical features 
alone over half the cases of monogenic diabetes would be missed. By combining the two 
biomarkers we increase the discriminatory ability and allow the clinician to pick up even 
atypical cases and rarer forms of monogenic diabetes, which traditional criteria may miss. 
The use of clinical features, however, results in fewer cases being sent for genetic testing 
that are negative, which clearly has cost implications.  The most cost effective approach is 
likely to involve a combination of biomarkers and clinical features.  Further studies are 
needed to determine whether the pick-up rate could be further improved by integrating the 
pathway with clinical features, such as the MODY calculator, or whether this would result in 
more missed patients as a consequence of reduced testing.   
In this study we also systematically tested all known genes for monogenic diabetes, rather 
than just the most common MODY genes (GCK, HNF1A and HNF4A).  9/17 (53%) of the cases 
identified as part of our cohort had mutations identified through additional testing on the 
targeted capture and 17/51 (33%) of all the monogenic diabetes cases found in total had 
mutations in other genes, highlighting the advantage of further testing using targeted next 
generation sequencing. 
 
Health economic evaluation of the pathway for detecting the common forms of MODY (GCK, 
HNF1A and HNF4A) has been carried out as a separate project, which has shown the 
pathway to be cost-saving (Peters et al, manuscript under review, abstract/protocol 
available(20; 21)).  The cost-effectiveness of additional testing for other forms of monogenic 
diabetes has not been assessed.  Due to the rarity of other monogenic diabetes there are 
little data available to inform such analyses.  Treatment change from insulin to 
sulphonylureas is still possible in cases diagnosed with ABCC8 and KCNJ11(29; 30), and for 
other genes where treatment change is not an option, a confirmed diagnosis can still help 
with management, prognosis and advice on risk to other family members(4).  The decision 
whether to pay for the more expensive, but more comprehensive next generation 
sequencing, rather than Sanger sequencing for MODY genes only, would depend on 
assessing the trade-offs of additional costs with long term benefits to the patient.  The 
presence of additional clinical features (e.g. renal cysts associated with HNF1B) may also 
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point to specific monogenic diagnoses and increase the likelihood of a positive genetic test 
result. 
 
A limitation of our study was that we had small numbers of patients with monogenic 
diabetes on which to evaluate the sensitivity of the pathway.  Considerably larger studies 
have shown the biomarkers individually to be highly sensitive for monogenic diabetes (99% 
for UCPCR(10; 11) and >99% for islet autoantibodies(13)), and by using both of these 
markers in a pathway the number of missed cases should be minimal at a population level 
(2% of 3.6% = 0.07%, reflected in the NPV of 99.9%).  Although there have been reports of 
MODY patients who are positive for islet autoantibodies (reviewed in (13)), these are rare 
and are likely to be cases with coincidental Type 1 diabetes. Previous studies reporting high 
prevalence of positive autoantibodies in their cohort have included clinically defined, rather 
than genetically confirmed MODY(31)  or use low cutoffs for antibody positivity, which can 
be inappropriate(32), so are likely to represent an overestimate.  There is also the potential 
for missed cases based on UCPCR, but again, the number of these patients will be small, and 
as they have insulin levels suggestive of Type 1 diabetes(33) they are unlikely to be able to 
transfer off insulin even if a genetic diagnosis is made.     
 
A further limitation is that despite screening using C-peptide and antibody testing the 
positive predictive value is still fairly low at 20%, indicating 4 out of 5 screened will not have 
a monogenic cause identified on diagnostic molecular genetic testing.  However, the aim of 
our screening pathway is that it is used purely as a tool to narrow down those individuals 
who would be more appropriate for genetic testing. This approach is a vast improvement 
over no screening (which would represent a PPV at the background prevalence rate of 
3.6%), misses fewer cases than using clinical features alone, and is at a level that has been 
shown to be cost-effective (manuscript under review, protocol and abstract available(20; 
21)).  Furthermore, the screening pathway still provides useful test results for this age group 
that offer additional information to support patient care.   Patients with severe insulin 
deficiency as determined by very low C-peptide values, will not respond to non-insulin 
therapy(33).  Positive C-peptide and negative antibody results are important clinically to 
highlight atypical cases of Type 1 diabetes or where other forms of diabetes, such as young-
onset Type 2 diabetes should be considered.  Patients with very high endogenous insulin 
without islet autoantibodies and no mutations in monogenic diabetes genes, are likely to 
have Type 2 diabetes, and may be able to manage on non-insulin treatment.   
 
Finally, this study comprised a 98% White Caucasian population and assesses patients at a 
median of 14 years after diagnosis.  Assessment of the pathway in other racial groups and in 
patients close to diagnosis is needed. 
 
In conclusion, we have demonstrated a simple, cheap, effective screening pathway that 
could be implemented at a population level to help correctly diagnose patients with 
monogenic diabetes. 
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Figure Legends 
 
Figure 1 – The UNITED biomarker screening pathway to investigate etiology of diabetes in 
patients diagnosed <30y:  Genetic testing is carried out on all patients who have 
endogenous insulin (UCPCR>0.2nmol/mmol) and who do not have either GAD or IA2 islet 
autoantibodies.  Patients without endogenous insulin or have GAD and/or IA2 islet 
autoantibodies are classed as having Type 1 diabetes.   
 
 
Figure 2 – Flow chart of patients recruited as part of UNITED.  Biomarker screening pathway 
in 1376 patients with no known genetic cause for their diabetes in Exeter and Tayside.  11 
dropped out.  17 new cases of monogenic diabetes detected (*one case identified through 
exome sequencing) 
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Table 1 – Characteristics of patients diagnosed with monogenic diabetes and details of mutations found for a) those recruited but diagnosed with 
monogenic diabetes prior to the study, and b) those diagnosed as a result of the biomarker pathway.  References for the genes and further details of the 
mutations are in Supplemental Table S3. 
 
a) Recruited but diagnosed prior to the UNITED study 
 Genetic characteristics Clinical characteristics 
ID Gene Method  Zygosity DNA level desc Age 
dx 
Treatment Parent 
DM 
BMI HbA1c Age rec Additional clinical features 
211 GCK Sanger Het c.97_117dup 3 Diet Yes 34.0 48 16   
523 GCK Sanger Het c.97_117dup 27 Diet No 51.7 55 43   
537 GCK Sanger Het c.683C>T 11 Diet Yes - - 13   
538 GCK Sanger Het c.683C>T 9 Diet Yes - - 11   
542 GCK Sanger Het c.184G>A 29 Diet Yes 38.9 48 39   
543 GCK Sanger Het c.184G>A 4 Diet Yes - - 4   
544 GCK Sanger Het c.184G>A 3 Diet Yes - - 5   
1155 GCK Sanger Het c.1343G>T 25 Diet Yes 19.3 50 25   
82095 GCK Sanger Het c.1019G>T 9 Diet Yes 21.9 45 14   
535 HNF1A Sanger Het c.379_381del 24 OHA Yes 25.9 51 47   
547 HNF1A Sanger Het c.1748G>A 22 Diet Yes 24.4 40 30 Low renal threshold 
554 HNF1A Sanger Het c.872dup 18 OHA Yes 30 86 39   
566 HNF1A Sanger Het c.872dup 17 OHA Yes 29.2 51 42 Sulphonylurea sensitivity, low renal threshold 
603 HNF1A Sanger Het c.1420C>T 20 OHA Yes 26.5 56 42 Low renal threshold 
617 HNF1A Sanger Het c.779C>T 25 Diet Yes 25.4 44 26   
892 HNF1A Sanger Het c.476G>A 14 Insulin Yes 30.0 63 40   
1370 HNF1A Sanger Het c.872dup 21 Diet Yes 36.1 83 21   
1409 HNF1A Sanger Het c.872dup 21 OHA+Ins Yes 32.8 95 42 Sulphonylurea sensitivity 
80480 HNF1A Sanger Het c.1093_1107+6del 19 OHA - 22.9 73 40   
82261 HNF1A Sanger Het c.185del 12 OHA+Ins Yes 23.7 73 25 Low renal threshold 
82276 HNF1A Sanger Het c.434C>T 13 Insulin Yes 23.8 60 27   
82301 HNF1A Sanger Het c.1340C>T 20 OHA Yes 27.4 91 37   
82310 HNF1A Sanger Het c.185del 18 OHA Yes 24.4 48 45 Low renal threshold 
82374 HNF1A Sanger Het c.1093_1107+6del 19 OHA Yes 23.8 83 20 Sulphonylurea sensitivity 
82258 HNF4A Sanger Het c.322G>A 28 Insulin Yes 20.9 60 31   
600 HNF1B Sanger Het c.982_986del 20 Insulin No 23.4 122 35 Renal cysts 
82033 HNF1B Sanger Het c.466A>G 17 Insulin No 25.3 54 35 Genital tract malformations, renal hypoplasia 
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82006 KCNJ11 Sanger Het c.601C>T 0 OHA No 26.6 33 35 Diagnosed at 12 weeks of age 
539 LMNA Sanger Het c.1930C>T 17 OHA+Ins Yes 24.2 114 49 Lipodystrophy  
595 LMNA Sanger Het c.1444C>T 21 OHA+Ins Yes 25.1 62 34   
604 3243  Hp m.3243A>G 27 Insulin Yes 26.9 54 36   
80541 3243  Hp m.3243A>G 28 Insulin Yes 26.4 83 48   
82399 3243  Hp m.3243A>G 29 Insulin Yes 26.4 56 41 Deafness 
540 NEUROD1 Sanger Het c.616dup 21 OHA+Ins Yes 49.8 83 36 Lipodystrophy and necrobiosis 
b) Identified as part of the biomarker pathway 
82372 GCK Sanger Het c.1340G>A 18 Diet No 25.5 46 19   
82316 HNF4A Sanger Het c.1064-5_1070del 14 Diet Yes 32.3 38 33   
377 HNF4A Sanger Het c.-12G>A 11 Insulin Yes 28.4 104 14   
80089 HNF1A Sanger Het c.1349dup 30 Insulin Yes 31.0 72 48   
80170 HNF1A Sanger Het c.391C>T 21 Insulin No 23.5 52 35 Low renal threshold 
80173 HNF1A Sanger Het c.495G>C 17 Insulin Yes 24.5 56 46   
82003 HNF1A Sanger Het c.28A>C 26 Diet Yes 29.8 73 26   
82352 HNF1A Sanger Het c.814C>T 13 Insulin Yes 32.3 91 45   
82013 HNF1A tNGS Het c.-258A>G 24 OHA Yes 39.6 75 43   
307 
HNF1B tNGS Het c.1-?_1674+?del 29 Insulin No 22.7 62 31 Aspergers, renal cysts, low fecal elastase low 
magnesium  
82014 NEUROD1 tNGS Het c.616dup 21 OHA No 35.3 88 31   
183 NEUROD1 tNGS Het c.616dup 29 Insulin No 27.1 55 46   
82010 3243 tNGS Hp m.3243A>G 27 OHA+Ins Yes 28.6 91 46   
82038 PPARG tNGS Het c.1154G>A 22 OHA No 26.6 53 36 Lipodystrophy, acanthosis 
80925 TRMT10A tNGS Hom c.79G>T 23 OHA+Ins No 33.0 69 28 Microcephaly, learning difficulties, epilepsy 
17 
WFS1 tNGS C/Het c.874C>T & c.877del 20 Insulin n/k 21.8 42 24 Bilateral Optic atrophy, neurogenic bladder, 
diet treatment, muscle pain on exercise 
175 
POLD1 Exome Het c.1812-1814del 14 OHA no 18.6 30 21 total lipodystrophy, sensori-neural deafness, 
mandibular hypoplasia, hypogonadism, 
undescended testes, severe insulin resistance 
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Table 2:  Positive and negative predictive values for the biomarker pathway, traditional MODY criteria (age at diagnosis <25y, non-insulin treated, parent 
affected with diabetes) and the MODY probability calculator (using a probability >25%, the pick-up rate for the diagnostic laboratory).  Prevalence is the 
proportion of diagnosed monogenic diabetes, PPV is the positive predictive value, NPV is the negative predictive value, percentage of monogenic cases 
missed is the proportion of monogenic cases not picked up by the approach, and number needed to test is 1/PPV.   
 
 N Prevalence of 
monogenic 
diabetes 
PPV (%) NPV (%) % of monogenic 
cases missed 
 
Number needed to test 
Biomarker pathway 1407 3.6% (51/1407) 20.0% 99.91% 0% 5 
Traditional MODY criteria 1362 3.6% (49/1362) 57.6% 97.7%  63% 2 
MODY Probability calculator 1347 3.3% (45/1347) 40.4% 98.3% 55% 3 
 
